US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eleven Biotherapeutics

3.29

0.0000

Volume:- -

Turnover:- -

Market Cap:159.20M

PE:-3.37

High:3.29

Open:3.29

Low:3.29

Close:3.29

52wk High:3.50

52wk Low:0.6201

Shares:48.39M

Float Shares:6.75M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.9768

ROE:--

ROA:--

PB:6.67

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Eleven Biotherapeutics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.elevenbio.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Eleven Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its lead product candidate is EBI-005, which has completed Phase III clinical trials for the treatment of patients with dry eye disease and allergic conjunctivitis. The company is also developing EBI-031 that is in preclinical development to treat diabetic macular edema; and a product candidate as an intravitreal injection for the treatment of certain retinal diseases, such as wet age-related macular degeneration. Eleven Biotherapeutics, Inc. has a collaboration and license agreement with ThromboGenics N.V. to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease. The company was founded in 2008 and is based in Cambridge, Massachusetts.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EBIO/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EBIO\",,,,,undefined,":{"symbol":"EBIO","market":"US","secType":"STK","nameCN":"Eleven Biotherapeutics","latestPrice":3.29,"timestamp":1526500800000,"preClose":3.29,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":6754972,"shares":48390072,"eps":-0.976817,"marketStatus":"Delisted","change":0,"latestTime":"02-11 10:28:49 EST","open":3.29,"high":3.29,"low":3.29,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.976817,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770843600000},"marketStatusCode":2,"symbolChange":{"newSymbol":"SESN","executeDate":"2018-05-17"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.29,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EBIO\",,,,,undefined,":{"symbol":"EBIO","floatShares":6754972,"roa":"--","roe":"--","lyrEps":0,"shares":48390072,"dividePrice":0,"high":3.29,"amplitude":0,"preClose":3.29,"low":3.29,"week52Low":0.6201,"pbRate":"6.67","week52High":3.5,"institutionHeld":0,"latestPrice":3.29,"eps":-0.976817,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.976817,"open":3.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EBIO\",params:#limit:5,,,undefined,":[{"date":"2018-05-17","symbol":"EBIO","newSymbol":"SESN","type":"symbolChange","dateTimestamp":1526529600000},{"market":"US","date":"2018-05-15","symbol":"EBIO","fiscalQuarterEnding":"2018/03","expectedEps":-0.13,"name":null,"time":"","type":"earning","dateTimestamp":1526356800000,"reportTimeType":"","actualEps":-0.11},{"market":"US","date":"2018-04-04","symbol":"EBIO","fiscalQuarterEnding":"2017/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1522814400000,"reportTimeType":"","actualEps":-0.22},{"market":"US","date":"2017-11-20","symbol":"EBIO","name":"Eleven Biotherapeutics Inc.","time":"","type":"earning","dateTimestamp":1511154000000,"reportTimeType":"","actualEps":-0.37},{"market":"US","date":"2017-11-14","symbol":"EBIO","fiscalQuarterEnding":"2017/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1510635600000,"reportTimeType":"pre","actualEps":0.91}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EBIO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.elevenbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eleven Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its lead product candidate is EBI-005, which has completed Phase III clinical trials for the treatment of patients with dry eye disease and allergic conjunctivitis. The company is also developing EBI-031 that is in preclinical development to treat diabetic macular edema; and a product candidate as an intravitreal injection for the treatment of certain retinal diseases, such as wet age-related macular degeneration. Eleven Biotherapeutics, Inc. has a collaboration and license agreement with ThromboGenics N.V. to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease. The company was founded in 2008 and is based in Cambridge, Massachusetts.","exchange":"NASDAQ","name":"Eleven Biotherapeutics","nameEN":"Eleven Biotherapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"EBIO\",market:\"US\",,,undefined,":null}}